Alzheimer Disease Research Report 2018: New Drugs, Markets and Companies 2017-2027 – Clinical Features …

DUBLIN–()–The “Alzheimer
Disease – New Drugs, Markets and Companies”
report from Jain
PharmaBiotech has been added to’s

The current management of Alzheimer’s disease is reviewed and it
involves a multidisciplinary approach. Acetylcholinesterase inhibitors
are mostly a symptomatic treatment but some claims are made about a
neuroprotective effect. Currently the only approved neuroprotective
therapy in is memantine. Management of these patients also require
neuroleptics for aggressive behavior and antidepressants. There is an
emphasis on early detection at the stage of mild cognitive impairment
and early institution of neuroprotective measures. The value of mental
exercise in delaying the onset of Alzheimer’s disease is being

Research in Alzheimer’s disease still aims at elucidating the basic
pathomechanisms. Animal models are important for research, particularly
in testing some of the potential therapeutic approaches. There is
considerable research in progress at the various centers, some of which
is funded by the National Institute of Aging of the National Institutes
of Health.

Over 300 different compounds are at various stages of development for
the treatment of Alzheimer’s disease. These are classified and
described. There are non-pharmacological approaches such as vagal nerve
stimulation and cerebrospinal fluid shunting, which are in clinical
trials. As of Jan 2018, the number of clinical trials of AD on US
Government clinical trials web site was over 1800. Selected 224 clinical
trials are listed, of which 151 are still in progress and 73 were
discontinued for various reasons.

Alzheimer’s disease market in the seven major markets is analyzed for
the year 2017. Several new therapies are expected to be in the market
and the shares of various types of approaches are estimated for the
future up to the year 2027. As a background to the markets,
pharmacoeconomic aspects of care of Alzheimer disease patients and
patterns of practice are reviewed in the seven major markets.

Profiles of 121 companies involved in developing diagnostics and
therapeutics for Alzheimer’s disease are presented along with 92
collaborations. The bibliography contains over 900 publications that are
cited in the report.The report is supplemented with 47 tables and 24

Key Topics Covered:

Executive Summary

1. Clinical Features, Epidemiology and Pathology

2. Diagnostic Procedures for Alzheimer Disease

3. Management of Alzheimer Disease

4. Research in Alzheimer Disease

5. Drug Discovery & Development for Alzheimer Disease

6. Markets & Finances of AD Care

7. Companies

8. References

For more information about this report visit

Source link

Leave a Reply

Your email address will not be published.